Skip Navigation


Rheumatology Advance Access originally published online on January 7, 2008
Rheumatology 2008 47(3):376-377; doi:10.1093/rheumatology/kem332
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/3/376    most recent
kem332v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wenham, C.
Right arrow Articles by Deighton, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wenham, C.
Right arrow Articles by Deighton, C.
Related Collections
Right arrow Spondylarthropathies
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Three significant cases of neutropenia with etanercept

C. Wenham, K. Gadsby and C. Deighton

Department of Rheumatology, Derbyshire Royal Infirmary, Derby, DE1 2QY, UK

Correspondence to: C. Deighton, Department of Rheumatology, Derbyshire Royal Infirmary, Derby, DE1 2QY, UK. E-mail: chris.deighton@derbyhospitals.nhs.uk

The first 10% of the full text of this article appears below.

SIR, Current BSR guidelines do not recommend regular blood count monitoring for anti-TNF therapy [1] as studies have suggested no increase in adverse haematological events [2–4]. We have noted a minority (14.3%) of our patients becoming neutropenic (<2.0 x 109/l) on anti-TNF [5], predominantly asymptomatically [5]. However, not all episodes have been without concern. Here we describe three cases of significant neutropenia on etanercept.

A 57-yr-old lady with aggressive seropositive RA since 1984 was intolerant of multiple DMARDs. She was on methotrexate and prednisolone (<10 mg), but . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?